- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Multiple sclerosis
- Meeting Date: July 2022
- Public Summary Document (PSD) July 2022 PBAC Meeting - (PDF 350KB)
- Public Summary Document (PSD) July 2022 PBAC Meeting - (Word 59KB)
Natalizumab – July 2022
Natalizumab: Solution concentrate for I.V. infusion 300 mg in 15 mL; Tysabri®
Last updated
28 October 2022